OPTIMISE-CKD Drug Utilization

Completed

Conditions studied: Chronic Kidney Disease

In brief

This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).

Key facts

Study ID

NCT05932901

Run by

AstraZeneca

People needed

2682052

Starts

2022-05-04

Expected to finish

2023-09-28

Last updated by the study team

2024-04-17

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (aged ≥18 years)
• Chronic kidney disease (diagnosis code, uACR >30mg/g or 2 eGFR ≥90 days apart, second value ≥75ml/min/1.73m2)
• ≥365 days continuous enrolment in database

You may not qualify if…

• History of type 1 diabetes, gestational diabetes or dialysis
• History of dapagliflozin 10mg prescriptions before index date

Where it is running

• Research Site — Minneota, Minnesota, United States
• Research Site — Kyoto, Kyoto, Japan
• Research Site — Tokyo, Japan
• Research Site — Uppsala, Sweden
• Research Site — Uppsala, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.